Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 5/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29024848 | 0.89 | PARP15 (0.64) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL14863368 | 0.87 | TDP1 (0.68) | TDP1 | |
| SCHEMBL14862577 | 0.84 | CXCR1 (0.50) | — | |
| SCHEMBL7723342 | 0.83 | PARP15 (0.42) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL7450653 | 0.79 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL24180195 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2SIGMAR1 | |
| SCHEMBL2665020 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL9966867 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL1263048 | 0.78 | PARP15 (0.59) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL3667235 | 0.78 | PARP15 (0.55) | PARP15PARP10PARP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2948442-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-9278954-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9278954-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9169205-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169205-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2006055245-A2 | PROCESS FOR PREPARING PYRAZOLOPYRIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| CN-1505613-A | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents | ʷ��˿�������ȳ�ķ����˾ | 2004-06-16 | — | — | CN | disclosed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | disclosed |
| EP-1341761-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002030895-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | PARP15 366/4885PARP10 381/4885PARP2 1081/4885 |
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | ACACB, PC, ACACA | PARP15 152/4885PARP10 544/4885PARP2 127/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | PARP15 815/4885PARP10 807/4885PARP2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.